{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T07:42:40Z","timestamp":1696059760095},"reference-count":53,"publisher":"Wiley","issue":"S6","license":[{"start":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T00:00:00Z","timestamp":1479686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Basierend auf den Daten zahlreicher Studien sind orale Tetracycline \u2013 und hier insbesondere Doxycyclin als Tetracyclin der zweiten Generation \u2013 die Grundpfeiler der systemischen Rosazea\u2010Therapie. Bisher ist daf\u00fcr jedoch nur Doxycyclin 40 mg in antientz\u00fcndlicher Dosierung mit ver\u00e4nderter Wirkstofffreisetzung zugelassen. Seit Einf\u00fchrung der Therapie mit Doxycyclin einmal t\u00e4glich in nicht antibiotischer Dosierung wird die orale Therapie h\u00e4ufiger als Erstbehandlung bei mittelschwerer bis schwerer papulopustul\u00f6ser Rosazea verschrieben. Oft wird diese Behandlung aufgrund der besseren Wirksamkeit im Vergleich zur Monotherapie auch mit einer topischen Behandlung kombiniert. Obwohl in der Systemtherapie weitere, nicht zugelassene Wirkstoffe wie Makrolide, Isotretinoin und Carvedilol mit viel versprechenden Ergebnissen untersucht wurden, ist die vorliegende Erfahrung bisher begrenzt, so dass diese Substanzen speziellen Situationen vorbehalten bleiben sollten.<\/jats:p>","DOI":"10.1111\/ddg.13141_g","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T12:55:39Z","timestamp":1479732939000},"page":"29-37","source":"Crossref","is-referenced-by-count":0,"title":["Aktueller Stand der systemischen Rosazea\u2010Therapie"],"prefix":"10.1111","volume":"14","author":[{"given":"M","family":"Schaller","sequence":"first","affiliation":[{"name":"Universit\u00e4ts\u2010Hautklinik Klinikum der Universit\u00e4t T\u00fcbingen  Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Sch\u00f6fer","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Dermatologie, Venerologie und Allergologie Johann Wolfgang Goethe\u2010Universit\u00e4t  Frankfurt\/Main Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Homey","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Dermatologie Universit\u00e4tsklinikum D\u00fcsseldorf  Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Gieler","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Psychosomatische Medizin, Psychosomatische Dermatologie Universit\u00e4tsklinikum Gie\u00dfen  Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Dermatologie, Allergologie und Dermatochirurgie Helios Kliniken Wuppertal, Universit\u00e4t Witten\/Herdecke  Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TA","family":"Luger","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Hautkrankheiten, Allgemeine Dermatologie und Venerologie Universit\u00e4tsklinikum M\u00fcnster  Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Ruzicka","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Dermatologie und Allergologie Ludwig\u2010Maximilians\u2010Universit\u00e4t M\u00fcnchen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Steinhoff","sequence":"additional","affiliation":[{"name":"Department of Dermatology and UCD Charles Institute for Translational Dermatology University Collge Dublin  Dublin Irland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,11,21]]},"reference":[{"key":"e_1_2_16_2_1","first-page":"18","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies","volume":"93","author":"Del Rosso JQ","year":"2014","journal-title":"Cutis"},{"key":"e_1_2_16_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.08.027"},{"key":"e_1_2_16_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03751.x"},{"key":"e_1_2_16_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13143"},{"key":"e_1_2_16_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12101_suppl"},{"key":"e_1_2_16_7_1","first-page":"1","article-title":"Systemic Therapy for Rosacea","volume":"12","author":"Baldwin HE","year":"2007","journal-title":"Skin Therapy Letter"},{"key":"e_1_2_16_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)90376-X"},{"key":"e_1_2_16_9_1","doi-asserted-by":"crossref","unstructured":"SchallerM Sch\u00f6ferH HomeyB et\u00a0al.Rosacea Management: Update on general measures and topical treatment options.2016. J Dtsch Dermatol Ges 2016; 14(Suppl 6):17\u201328.","DOI":"10.1111\/ddg.13143"},{"key":"e_1_2_16_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.004"},{"key":"e_1_2_16_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003262.pub5"},{"key":"e_1_2_16_12_1","first-page":"411","article-title":"Second\u2010generation tetracyclines, a dermatologic overview: clinical uses and pharmacology","volume":"48","author":"Maibach H","year":"1991","journal-title":"Cutis"},{"key":"e_1_2_16_13_1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2340\/0001555572178179","article-title":"Effect of doxycycline on the generation of reactive oxygen species: a possible mechanism of action of acne therapy with doxycycline","volume":"72","author":"Akamatsu H","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_16_14_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.1.567"},{"key":"e_1_2_16_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.04.045"},{"key":"e_1_2_16_16_1","doi-asserted-by":"crossref","unstructured":"ReinholzM RuzickaT SteinhoffM et\u00a0al.Pathogenesis and clinical presentation of rosacea as a key for a symptom\u2010oriented therapy.2016. J Dtsch Dermatol Ges 2016; 14(Suppl 6):4\u201316.","DOI":"10.1111\/ddg.13139"},{"key":"e_1_2_16_17_1","first-page":"149","article-title":"Treatment of rosacea with doxycycline monohydrate","volume":"66","author":"Bikowski JB","year":"2000","journal-title":"Cutis"},{"key":"e_1_2_16_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2010.07345_supp.x"},{"key":"e_1_2_16_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2008.03445.x"},{"key":"e_1_2_16_20_1","doi-asserted-by":"publisher","DOI":"10.1586\/17469872.2.5.523"},{"key":"e_1_2_16_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.11.021"},{"key":"e_1_2_16_22_1","first-page":"664","article-title":"Anti\u2010inflammatory dose doxycycline in the treatment of rosacea","volume":"8","author":"Del Rosso JQ","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_16_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-9740.2003.03014.x"},{"key":"e_1_2_16_24_1","first-page":"641","article-title":"Combined effect of anti\u2010inflammatory dose doxycycline (40\u2010mg doxycycline, usp monohydrate controlled\u2010release capsules) and metronidazole topical gel 1 % in the treatment of rosacea","volume":"6","author":"Fowler JF","year":"2007","journal-title":"J Drugs Dermatol."},{"key":"e_1_2_16_25_1","first-page":"573","article-title":"Comparison of anti\u2010inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea","volume":"7","author":"Del Rosso JQ","year":"2008","journal-title":"J Drugs in Dermatol"},{"key":"e_1_2_16_26_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.3.541"},{"issue":"9","key":"e_1_2_16_27_1","first-page":"5S","article-title":"Clinical implications of the immunomodulatory effects of macrolides","volume":"117","author":"Tamaoki J","year":"2004","journal-title":"Am J Med"},{"key":"e_1_2_16_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2006.02322.x"},{"key":"e_1_2_16_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1997.00301.x"},{"key":"e_1_2_16_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.01958.x"},{"key":"e_1_2_16_31_1","doi-asserted-by":"publisher","DOI":"10.4065\/74.6.613"},{"key":"e_1_2_16_32_1","first-page":"54","article-title":"Use of oral isotretinoin in the management of rosacea","volume":"4","author":"Park H","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_16_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.01.025"},{"key":"e_1_2_16_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.03.033"},{"key":"e_1_2_16_35_1","unstructured":"NikolowskiJ PlewigG.Oral treatment of rosacea with 13\u2010cis\u2010retinoic acid Hautarzt1981;32:575\u201384."},{"key":"e_1_2_16_36_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2340\/00015555641521","article-title":"13\u2010cis\u2010Retinoic acid in rosacea. Clinical and laboratory findings","volume":"64","author":"Schmidt JB","year":"1984","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_16_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1986.tb04533.x"},{"key":"e_1_2_16_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1984.tb00842.x"},{"key":"e_1_2_16_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.111"},{"key":"e_1_2_16_40_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1064456"},{"key":"e_1_2_16_41_1","first-page":"301","volume-title":"Acne and Related Disorders","author":"Irvine C","year":"1989"},{"key":"e_1_2_16_42_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0888"},{"key":"e_1_2_16_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.204"},{"key":"e_1_2_16_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.04.017"},{"key":"e_1_2_16_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.04.041"},{"key":"e_1_2_16_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)71750-7"},{"key":"e_1_2_16_47_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archderm.1997.03890370055009","article-title":"Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline","volume":"133","author":"Quarterman MJ","year":"1997","journal-title":"Arch Dermatol"},{"key":"e_1_2_16_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2011.07723_suppl.x"},{"key":"e_1_2_16_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000051"},{"key":"e_1_2_16_50_1","unstructured":"Pers\u00f6nliche Mitteilung von Prof. Martin Schaller basierend auf einer nicht publizierte Beobachtung."},{"key":"e_1_2_16_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03132.x"},{"key":"e_1_2_16_52_1","first-page":"607","article-title":"Efficacy of topical azelaic acid (AzA) gel 15 % plus oral doxycycline 40 mg versus metronidazole gel 1 % plus oral doxycycline 40 mg in mild\u2010to\u2010moderate papulopustular rosacea","volume":"9","author":"Del Rosso JQ","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_16_53_1","first-page":"639","article-title":"A multicenter study of topical azelaic acid 15 % gel in combination with oral doxycycline as initial therapy and azelaic acid 15 % gel as maintenance monotherapy","volume":"8","author":"Thiboutot DM","year":"2009","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"e_1_2_16_54_1","first-page":"16","article-title":"Effectiveness and safety of doxycycline 40 mg (30\u2010mg immediate\u2010release and 10\u2010mg delayed\u2010release beads) once daily as add\u2010on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community\u2010based trial","volume":"86","author":"Del Rosso JQ","year":"2010","journal-title":"Cutis"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fddg.13141_g","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fddg.13141_g","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.13141_g","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T02:27:15Z","timestamp":1696040835000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.13141_g"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,21]]},"references-count":53,"journal-issue":{"issue":"S6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1111\/ddg.13141_g"],"URL":"https:\/\/doi.org\/10.1111\/ddg.13141_g","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,21]]}}}